Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05312151 · ClinicalTrials.gov registry record · Phase 2
The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder
A Phase 2 study, sponsored by COMPASS Pathways.
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT05312151: Completed Phase 2 study, sponsored by COMPASS Pathways.
NCT05312151 is a Phase 2 study that has completed, run by COMPASS Pathways. The registered enrollment target is 22 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05312151, a Phase 2 study, has completed, sponsored by COMPASS Pathways.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
The Safety and Tolerability of COMP360 in Participants with Post-traumatic Stress Disorder
Primary Outcome
A TEAE is defined as an adverse event (AE) that has an onset on or after the dose of study drug, or any pre-existing AE condition that has worsened on or after the dose of study drug.
Interventions
- DRUG Psilocybin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2022-06-10 |
| Est. Completion | 2024-02-12 |
| Phase | Phase 2 |
What the finished NCT05312151 record still lists
NCT05312151 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 1 intervention - of which Psilocybin is the first listed.
NCT05312151 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05312151 about?
NCT05312151 is a clinical study titled "The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder". The Safety and Tolerability of COMP360 in Participants with Post-traumatic Stress Disorder
What is the current status of trial NCT05312151?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2022-06-10. Estimated completion is 2024-02-12.
What interventions are being tested in trial NCT05312151?
The interventions under investigation include: Psilocybin (DRUG).
Who is sponsoring clinical trial NCT05312151?
This trial is sponsored by COMPASS Pathways, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05312151's enrollment target sits among peer trials
22 1790th of 2000 higher than 207 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI